Teva forecasts $3.7-3.9B of worldwide Copaxone sales in 2013, which is a slight decrease from 2012. Teva has not given guidance on US Copaxone sales, specifically; however, if the historical 74% of sales in the US holds, then Teva expects 2013 US Copaxone sales of about $2.9B. The actual amount will depend on Copaxone price increases (which are a near certainty) and on competition from BG-12 and other oral agents.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.